Certificate in Cancer Immunotherapy Module 6: Oncolytic Viruses and Local Therapy

Published 10/11/2021

Please note, this activity does not offer continuing education credit.

 

Course Description
This interactive online course is part of the Certificate in Cancer Immunotherapy program, produced by the Society for Immunotherapy of Cancer (SITC). The purpose of the certificate program is to provide hospitals, medical centers, third-party payers, referring physicians, trainees and patients with an identifiable designation for healthcare providers who can safely and effectively participate in administration of immunotherapies and manage patients treated with these approaches. View all eight modules of the program and a detailed description of the program here.

This course, Module 6: Oncolytic Viruses and Local Therapy, will cover the biological foundation and clinical implementation of intratumoral therapies and oncolytic viruses.


Target Audience
The program is available to licensed physicians (U.S. licensed MD / DO or global equivalent). The courses and earning of the certificate (SITC-G; G = graduate) are also available to practicing, licensed NPs, PAs, and PharmDs or global equivalent. RPh degree holders are eligible if they are involved in direct clinical services. The courses are available to others who are not practicing clinicians, but they will not be eligible to earn the certificate.

Faculty

Brian Gastman, MD
Professor, Department of Surgery, School of Medicine
Member, Hematopoietic and Immune Cancer Biology Program, Case Comprehensive Cancer Center
Case Western Reserve University, Cleveland, OH
Department of Plastic Surgery
Cleveland Clinic Main Campus, Cleveland, OH

Ann Silk, MD, MS
Co-Director of the Merkel Cell Carcinoma Center of Excellence
Dana-Farber Cancer Institute, Boston, MA
 

Learning Objectives

Topic At the conclusion of this activity, the participant should be able to:

Basic Mechanisms of Oncolytic Viruses
and Intralesional Therapy

  • Describe the rationale for intralesional therapy as a strategy for modulating tumor cells and promoting immunity.
  • Distinguish the differences between oncolytic viruses and non-viral intralesional approaches.  
  • Classify the different viruses available for cancer immunotherapy and their advantages and disadvantages.
  • List approved oncolytic viruses and intralesional agents.
  • Describe the dual mechanism of action of oncolytic viruses in mediating anti-tumor immunity.
  • Identify how oncolytic viruses can deliver transgenes to promote anti-tumor activity.
  • Describe alternative delivery routes of administration for oncolytic viruses and other intralesional agents.

Patient Selection and Monitoring
for Oncolytic Virus Therapies and Intralesional Therapy

  • Identify eligible patients for oncolytic viruses and intralesional therapy.
  • Determine when oncolytic viruses and/or intralesional therapy should be considered in patient management.
  • Select appropriate tumors for injection of an oncolytic virus and/or intralesional therapy.
  • Determine the volume of oncolytic virus and/or intralesional agent for patient therapy.
  • Describe the process of injecting oncolytic viruses and/or intralesional treatments in patients with cancer.
  • Identify the role of interventional radiology in administration of intralesional treatments to deep and/or visceral tumors.
  • Apply appropriate injection site management following injection of intralesional agents.
  • Define the patterns of response with oncolytic viruses and other intralesional treatments.
  • Identify contraindications to oncolytic virus and/or intralesional therapy.
  • Outline the potential role for oncolytic viruses and intralesional therapy as part of combination regimens for patients with cancer.

Management of Oncolytic Virus and intralesional therapy Adverse Events

  • Identify the most common adverse events seen with oncolytic viruses and/or other intralesional treatments.
  • Prescribe appropriate intervention for managing common adverse events associated with oncolytic viruses and intralesional therapies.

Logistical and Biosafety Issues
Associated with Oncolytic Virus Therapy

  • Describe the biosafety issues associated with oncolytic virus administration.
  • Recognize the potential for bioshedding and contact transmission associated with oncolytic viruses.
  • Explain how to modify patient flow to optimize integration of oncolytic viruses and intralesional treatments into clinical practice.
  • Implement standard operating procedures for safe delivery of oncolytic viruses and intralesional treatments into clinical practice.


 


SITC Online Education Disclaimer

 

A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.

 


Satisfactory Completion
Learners must listen to each self-directed audio recording while following along with the visual slides/read the articles, pass the post-test with a score of 80% or higher (unlimited attempts) and complete an evaluation form to receive a certificate of completion. To earn the SITC-G designation, you must participate in the entire activity.
 

Method of Participation and Request for Credit
During the period 10/11/2021 through 10/11/2023 participants must read the learning objectives and faculty disclosures and study the educational activity.

Once the participant has passed the post-test with a score of 80% or higher (unlimited attempts allowed), and the course evaluation has been completed, credit will be automatically requested to the CRO the participant has selected during the registration process. 

Certificates will be available to the participant for printing after passing the post-test and completing the course evaluation.

For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.


Media
Internet

Hardware and Software Requirements
SITC connectED requires a modern web browser (Edge, Apple Safari, Google Chrome, Internet Explorer 7+) and the ability to listen to audio with the content.

Disclosure of Unlabeled Use
This educational activity may contain a discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Interactive Course

Next, to view the course, close this window and you will be taken to the course menu page. Once there, refresh the course menu page and select View Now for the last topic.

\n
Individual topic purchase: Selected
Certificate of Participation (No Credit)
Certificate of Participation: 0.00
Products
Certificate in Cancer Immunotherapy Module 6: Oncolytic Viruses and Local Therapy
SITC Member Price:$25.00
Non-Member Price:$31.25